Italfarmaco

Italfarmaco company information, Employees & Contact Information

Explore related pages

Related company profiles:

Italfarmaco, one of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries. The company was founded in Milan in 1938. The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece, where it employs a workforce of over 1400 and has a total turnover exceeding 300 million euros. Its products, all of which have a high therapeutic content, are mainly used in the cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas.

Company Details

Employees
1.22K
Founded
-
Address
Calle San Rafael, 3, Alcobendas,comunidad De Madrid 28108,spain
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Alcobendas, Comunidad de Madrid
Looking for a particular Italfarmaco employee's phone or email?

Italfarmaco Questions

News

New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 Neuromuscular Study Group Annual Scientific Meeting - PR Newswire

New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 Neuromuscular Study Group Annual Scientific Meeting PR Newswire

Italfarmaco Announces Exclusive Distribution Agreement with Multicare Pharma for DMD Treatment Givinostat in Brazil - GlobeNewswire

Italfarmaco Announces Exclusive Distribution Agreement with Multicare Pharma for DMD Treatment Givinostat in Brazil GlobeNewswire

ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts - Yahoo Finance

ITF Therapeutics LLC Announces Opening of New U.S. Headquarters in Concord, Massachusetts Yahoo Finance

ITF Therapeutics Appoints Erica L. Monaco, CPA, as Chief Operating Officer - citybiz

ITF Therapeutics Appoints Erica L. Monaco, CPA, as Chief Operating Officer citybiz

ITF Therapeutics LLC to Present Patient-Reported Outcome Data for DUVYZAT® (givinostat) in Duchenne Muscular Dystrophy at ISPOR 2025 - PR Newswire

ITF Therapeutics LLC to Present Patient-Reported Outcome Data for DUVYZAT® (givinostat) in Duchenne Muscular Dystrophy at ISPOR 2025 PR Newswire

ITF Therapeutics LLC Presents Long-Term Data of DUVYZAT™ (givinostat) for Treatment of Duchenne Muscular Dystrophy at MDA Clinical and Scientific Conference - Yahoo Finance

ITF Therapeutics LLC Presents Long-Term Data of DUVYZAT™ (givinostat) for Treatment of Duchenne Muscular Dystrophy at MDA Clinical and Scientific Conference Yahoo Finance

Italfarmaco Announces U.S. FDA Grants Fast Track Designation to Givinostat in Treatment of Polycythemia Vera - GlobeNewswire

Italfarmaco Announces U.S. FDA Grants Fast Track Designation to Givinostat in Treatment of Polycythemia Vera GlobeNewswire

US FDA approves Italfarmaco's drug for Duchenne muscle-wasting disorder - Reuters

US FDA approves Italfarmaco's drug for Duchenne muscle-wasting disorder Reuters

FDA Extends Review Time for Italfarmaco’s Duchenne Agent Givinostat - NeurologyLive

FDA Extends Review Time for Italfarmaco’s Duchenne Agent Givinostat NeurologyLive

Italfarmaco's Duvyzat scores conditional EU nod for DMD treatment - FirstWord Pharma

Italfarmaco's Duvyzat scores conditional EU nod for DMD treatment FirstWord Pharma

Italfarmaco appoints Francesco Di Marco as CEO - The Pharma Letter

Italfarmaco appoints Francesco Di Marco as CEO The Pharma Letter

Italfarmaco closes on EU okay for Duchenne drug - pharmaphorum

Italfarmaco closes on EU okay for Duchenne drug pharmaphorum

Italfarmaco Provides Overview on Givinostat as Treatment for Duchenne Muscular Dystrophy: Progress in Global Access, Regulatory Milestones and Clinical Trials - Business Wire

Italfarmaco Provides Overview on Givinostat as Treatment for Duchenne Muscular Dystrophy: Progress in Global Access, Regulatory Milestones and Clinical Trials Business Wire

FDA Approves Italfarmaco's Givinostat for Duchenne Muscular Dystrophy - NeurologyLive

FDA Approves Italfarmaco's Givinostat for Duchenne Muscular Dystrophy NeurologyLive

ITF Therapeutics LLC Announces Multiple Data Presentations at 2025 MDA Clinical and Scientific Conference - PR Newswire

ITF Therapeutics LLC Announces Multiple Data Presentations at 2025 MDA Clinical and Scientific Conference PR Newswire

Italfarmaco Appoints Francesco Di Marco as Chief Executive Officer - GlobeNewswire

Italfarmaco Appoints Francesco Di Marco as Chief Executive Officer GlobeNewswire

ITF Therapeutics LLC Announces Appointment of Erica L. Monaco, CPA, as Chief Operating Officer - PR Newswire

ITF Therapeutics LLC Announces Appointment of Erica L. Monaco, CPA, as Chief Operating Officer PR Newswire

ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy - PR Newswire

ITF Therapeutics LLC Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Patients With Duchenne Muscular Dystrophy PR Newswire

Italfarmaco and Medis Announce Exclusive Distribution - GlobeNewswire

Italfarmaco and Medis Announce Exclusive Distribution GlobeNewswire

Italfarmaco Receives FDA Approval for Duvyzat™ (givinostat) in Duchenne Muscular Dystrophy - Business Wire

Italfarmaco Receives FDA Approval for Duvyzat™ (givinostat) in Duchenne Muscular Dystrophy Business Wire

Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Four European Countries - Business Wire

Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Four European Countries Business Wire

FDA approves DMD treatment from Italfarmaco - Chemical & Engineering News

FDA approves DMD treatment from Italfarmaco Chemical & Engineering News

Italfarmaco nabs FDA approval for new Duchenne med, teeing up sparring match with Sarepta - Fierce Pharma

Italfarmaco nabs FDA approval for new Duchenne med, teeing up sparring match with Sarepta Fierce Pharma

Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate - Business Wire

Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate Business Wire

MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy - PMLiVE

MHRA approves Italfarmaco’s Duvyzat to treat Duchenne muscular dystrophy PMLiVE

Results from Italfarmaco Pivotal Phase 3 EPIDYS Study of Givinostat in Duchenne Muscular Dystrophy (DMD) Published in The Lancet Neurology - Business Wire

Results from Italfarmaco Pivotal Phase 3 EPIDYS Study of Givinostat in Duchenne Muscular Dystrophy (DMD) Published in The Lancet Neurology Business Wire

Inhaled Form of Teicoplanin for CF Patients Goal of Italfarmaco, Neupharma Partnernership - Cystic Fibrosis News Today

Inhaled Form of Teicoplanin for CF Patients Goal of Italfarmaco, Neupharma Partnernership Cystic Fibrosis News Today

Top Italfarmaco Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant